No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Vaxcyte, Inc. (PCVX) stock was $64.67 as of Oct 6, 2026, 1:55 PM EDT, down 12.40% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +72.6% · 3-year avg +14.7%/yr · 5-year avg +25.1%/yr
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines.
Biotechnology · San Carlos, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2021-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 3, 2026
28 days away
EPS Estimate
-2.14
Revenue Est.
$12.50M
Last Quarter Results
EPS
$-1.97
vs Estimate
$-2.10
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PCVX | $9.34B | $64.67 | -12.40% | +72.59% | +25.08% | N/A | N/A |
| 2PODD | $9.38B | $135.48 | -0.10% | -55.95% | -13.93% | +13.11% | vs PCVX |
| 3BRKR | $9.29B | $61.02 | -4.45% | +72.96% | -3.42% | +11.49% | vs PCVX |
| 4KRYS | $9.61B | $325.92 | -2.67% | +82.10% | +44.28% | N/A | vs PCVX |
| 5HSIC | $9.65B | $84.72 | +0.58% | +25.52% | +1.39% | +2.90% | vs PCVX |
| 6AXSM | $9.00B | $174.95 | -1.20% | +46.93% | +41.40% | +35.76% | vs PCVX |
N/A
$0.00
vs Estimate
$12.50M
Consensus Rating
Based on 8 analysts
Average Price Target
$107.13
+65.6% upside
Low
$67.00
Current
$64.67
High
$163.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.32 | $-2.14 | $-1.94 | 4 |
| Quarter ending Dec 2026 | $-2.08 | $-2.08 | $-2.08 | 4 |
| Quarter ending Mar 2027 | $-1.21 | $-1.21 | $-1.21 | 1 |
| Quarter ending Jun 2027 | $-1.24 | $-1.24 | $-1.24 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-9.81 | $-8.27 | $-6.74 | 6 |
| FY 2027 | $-7.79 | $-6.58 | $-5.42 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $12.50M | $12.50M | $12.50M | 1 |
| Quarter ending Dec 2026 | $12.50M | $12.50M | $12.50M | 1 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $12.19M | $25.00M | $48.79M | 5 |
| FY 2027 | $87.15M | $87.15M | $87.15M | 9 |
